Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Ph 2 Trial in Advanced Ovarian Cancer May 7, 2024
Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen + Pembrolizumab for the Treatment of Recurrent Ovarian Cancer Announced April 16, 2024
REJOICE-Ovarian01 Ph 2/3 Trial of Raludotatug Deruxtecan Initiated in Platinum-Resistant Ovarian Cancer April 9, 2024
Stenoparib development Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer Accelerated April 2, 2024
First patient dosed in Ph 1b/2 trial of LB-100 + dostarlimab-gxly in ovarian clear cell carcinoma March 26, 2024
FDA Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for FRα-positive, platinum-resistant ovarian cancer (PROC) March 26, 2024
Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer March 12, 2024
FDA Clearance obtained for a First in Human Clinical Study for Stage III/IV Ovarian Cancer Treatment with Autologous Vaccine Therapy, Innocell™ March 12, 2024
Patients Enrolling in Ph 1/2 Clinical Trial of IMNN-001 + Avastin in Advanced Ovarian Cancer March 4, 2024
Dosing Initiated in Second Cohort of Ovarian Cancer FSHR-targeting CER-T Clinical Trial February 26, 2024
ProfoundBio Raises $112 Million in Oversubscribed Series B Equity Financing to Advance its Clinical-Stage ADC Pipeline February 26, 2024
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash February 26, 2024
23ME-00610 Ph 1/2a trial in advanced neuroendocrine and ovarian cancer patient cohorts expanded January 10, 2024
First Patient Dosed In Ph1/2 Trial Of TNG348 In Patients With BRCA1/2-Mutant and Other HRD+ Cancers January 10, 2024
Rinatabart Sesutecan FDA Fast Track Designation for Patients with Advanced Ovarian Cancer January 10, 2024
Confirmatory Ph 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer initiated December 19, 2023
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio December 11, 2023
FDA Grants Priority Review of Supplemental BLA for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer December 11, 2023
Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population Announced December 4, 2023
